BBNX · XBRL financial data
Beta Bionics financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BBNX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue from contracts with customers | 65,124 | 100,251 |
| Cost of goods and services sold | 29,236 | 44,714 |
| Gross profit | 35,888 | 55,537 |
| Research and development | 26,184 | 34,789 |
| General and administrative | 17,869 | 31,025 |
| Total operating expenses | 81,139 | 127,218 |
| Operating income (loss) | (45,251) | (71,681) |
| Interest income | 3,909 | 10,932 |
| Other income (expense) | (2) | (1) |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (54,756) | (73,200) |
| Earnings per share, basic USD per share | (8.60) | (1.81) |
| Earnings per share, diluted USD per share | (8.60) | (1.81) |
| Weighted average shares, basic thousands of shares | 6,365 | 40,529 |
| Weighted average shares, diluted thousands of shares | 6,365 | 40,529 |
Balance sheet
CSVFiscal years (BBNX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 30,432 | 31,576 |
| Short-term investments | 73,143 | 187,549 |
| Accounts receivable | 11,996 | 17,118 |
| Inventory | 13,320 | 21,722 |
| Prepaid and other current assets | 4,032 | 9,840 |
| Total current assets | 132,923 | 267,905 |
| Property and equipment, net | 4,776 | 8,600 |
| Right-of-use asset | 6,645 | 6,627 |
| Total assets | 149,645 | 328,743 |
| Accounts payable | 2,852 | 4,998 |
| Total current liabilities | 21,148 | 30,924 |
| Lease liability, non-current | 5,726 | 5,365 |
| Total liabilities | 73,632 | 41,133 |
| Accumulated deficit | (296,737) | (369,937) |
| Total stockholders' equity | (245,360) | 287,610 |
| Total liabilities and equity | 149,645 | 328,743 |
| Common shares outstanding (cover page) thousands of shares | 43,349 | 44,382 |
Cash flows
CSVFiscal years (BBNX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (54,756) | (73,200) |
| Stock-based compensation | 6,384 | 16,384 |
| Net cash from operating activities | (48,273) | (50,925) |
| Purchases of property and equipment | 3,395 | 5,297 |
| Net cash from investing activities | (3,476) | (162,805) |
| Proceeds from issuing common stock | — | 194,526 |
| Net cash from financing activities | 55,615 | 214,874 |
| Net change in cash | 3,866 | 1,144 |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Beta Bionics | 81,551 | 35,505 | (12,287)* | 54.4M | 13.0 quarters | 10-QSep 30, 2026 |
| Kestra Medical Technologies | 68,558 | 30,971 | (32,295) | 59.6M | 4.9 quarters | 10-QJul 31, 2026 |
| Cadre Holdings | 63,916 | 202,876 | 22,933* | 42.9M | — | 10-QSep 30, 2026 |
| Avanos Medical | 65,600 | 182,200 | (12,300) | 46.8M | 5.3 quarters | 10-QMar 31, 2026 |
| Mimedx Group | 120,791 | 62,283 | 3,919* | 145.9M | — | 10-QSep 30, 2026 |
| Embecta | 214,700 | 271,700 | 41,800* | 56.7M | — | 10-QJun 30, 2026 |
| SI-BONE | 35,311 | 55,704 | 5,940* | 45.1M | — | 10-QSep 30, 2026 |
| Iradimed | 63,288 | 24,203 | 6,997* | 12.8M | — | 10-QSep 30, 2026 |
| Biolife Solutions | 23,997 | not reported | 6,348* | 48.9M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.